# US 2006/0153865 A1 · Antigenic peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153865 A1
- Document ID: US20060153865A1
- Status: Published application
- Kind: A1
- Application number: 10/529,885
- Filed: 2003-08-19
- Published: 2006-07-13
- Earliest claimed: 2002-10-03
- Inventors: Amir Maksyutov; Alexander Ryzhikov; Alexander Kolobov; Zaki Maksyutov
- Web page: https://patentgrep.com/patent/US20060153865A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 1/047: {Simultaneous synthesis of different peptide species; Peptide libraries}
- C07K 14/35: from Mycobacteriaceae (F)
- C07K 14/445: Plasmodium
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16111: concerning HIV env
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for designing antigenic peptide libraries accounts for naturally occurring and potential variability in a group of protein sequences from a variable pathogen. The peptide libraries can elicit an immune response against a range of pathogen variants.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A composition comprising a family of antigenic peptides having amino acid sequences having antigenic similarity to amino acid sequences of a variable region of a pathogen protein, wherein each antigenic peptide in the family has at least one amino acid position that varies relative to other antigenic peptides in the family.

### Claim 30 (depends on 29)

The composition of claim 29, wherein one amino acid residue occurs more frequently than another in the position that varies.

### Claim 31 (depends on 29)

The composition of claim 29, wherein the family includes greater than 150 mutually unique antigenic peptides.

### Claim 32 (depends on 29)

The composition of claim 29, wherein the family includes greater than 1,000 mutually unique antigenic peptides.

### Claim 33 (depends on 29)

The composition of claim 29, wherein the family includes fewer than 100,000 mutually unique antigenic peptides.

### Claim 34 (depends on 29)

The composition of claim 29, wherein the family includes fewer than 50,000 mutually unique antigenic peptides.

### Claim 35 (depends on 29)

The composition of claim 29, wherein the family includes between 1,000 and 50,000 mutually unique antigenic peptides.

### Claim 36 (depends on 29)

The composition of claim 29, wherein the pathogen protein is HIV gp120.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the variable region is selected from the group consisting of the V1 region, the V2 region, the V3 region, the V4 region and the V5 region.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the family of antigenic peptides includes sequences having antigenic similarity to sequences from a subtype of HIV.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the subtype is selected from the group consisting of subtype A, subtype B, subtype C, subtype D, subtype F, subtype G, a recombinant subtype, a subtype of HIV group N, a subtype of HIV group O, and combinations thereof.

### Claim 40 (depends on 29)

The composition of claim 29, wherein at least two members of the family of antigenic peptides are mixed together.

### Claim 41 (depends on 29)

The composition of claim 29, wherein the family of antigenic peptides are separated according to sequence.

### Claim 42 (depends on 29)

The composition of claim 29, wherein the family includes a multiple antigenic peptide.

### Claim at position 16

43-101. (canceled)

### Claim 102

A peptide library comprising a family of peptides including the fragment:
—N—N—T—R—K—X4—I—X5—X6—G—X7—G—X8—X9—X10—X11—X12—T—X13—X14—I—X15—G—X16—I—R—
wherein each X4-X16 is a fragment zero, one, two or three amino acid residues in length.

### Claim 103 (depends on 102)

The peptide library of claim 102, wherein the family has antigenic similarity to the V3 region of HIV gp120.

### Claim 104 (depends on 103)

The peptide library of claim 103, wherein the family has antigenic similarity to the V3 region of HIV gp120 of HIV subtype B.

### Claim 105 (depends on 102)

The peptide library of claim 102, wherein the family of peptides have the formula:
X1—C—X2—R—P—X3—N—N—T—R—K—X4—I—X5—X6—G—X7—G—X8—X9—X10—X11—X12—T—X13—X14—I—X15—G—X16—I—R—X17—A—X18—C—X19
wherein each X1-X19 is a fragment zero, one, two or three amino acid residues in length.

### Claim 106 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X1 independently is N, T, or H.

### Claim 107 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X2 independently is T or I.

### Claim 108 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X3 independently is N, S, or G.

### Claim 109 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X4 independently is S, G, or R.

### Claim 110 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X5 independently is H, P, N, T or Y.

### Claim 111 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X6 independently is I or M.

### Claim 112 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X7 independently is P, L, or W.

### Claim 113 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X8 independently is R, Q, G or S.

### Claim 114 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X9 independently is A, V or T.

### Claim 115 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X10 independently is F, W, or V.

### Claim 116 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X11 independently is Y, F or H.

### Claim 117 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X12 independently is T or A.

### Claim 118 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X13 independently is G, E or R.

### Claim 119 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X14 independently is E, Q, R or G.

### Claim 120 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X15 independently is I or T.

### Claim 121 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X16 independently is D or N.

### Claim 122 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X17 independently is Q or K.

### Claim 123 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X18 independently is H or Y.

### Claim 124 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X19 independently is N or T.

### Claim 125 (depends on 105)

The peptide library of claim 105, wherein for each peptide of the family, X1 independently is N, T or H; X2 independently is T or I; X3 independently is N, S, or G; X4 independently is S, G, or R; X5 independently is H, P, N, T or Y; X6 independently is I or M; X7 independently is P, L, or W; X8 independently is R, Q, G or S; X9 independently is A, V or T; X10 independently is F, W, or V; X11 independently is Y, F or H; X12 independently is T or A; X13 independently is G, E or R; X14 independently is E, Q, R or G; X15 independently is I or T; X16 independently is D or N; X17 independently is Q or K; X18 independently is H or Y; and X19 independently is N or T.

### Claim 126 (depends on 105)

The peptide library of claim 105, wherein at least two members of the family of peptides are mixed together.

### Claim 127 (depends on 105)

The peptide library of claim 105, wherein the family of peptides are separated according to sequence.

### Claim 128 (depends on 105)

The peptide library of claim 105, wherein the family includes greater than 150 mutually unique peptide sequences.

### Claim 129 (depends on 105)

The peptide library of claim 105, wherein the family includes fewer than 100,000 mutually unique peptide sequences.

### Claim 130 (depends on 105)

The peptide library of claim 105, wherein the family includes fewer than 500 mutually unique peptide sequences, the sequences being representative of the entire sequence diversity available.

### Claim at position 46

131-279. (canceled)
